Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

Witzig, Thomas E.; Li, Gordon; Cabanillas, Fernando; Czuczman, Myron S.; Emmanouilides, Christos; Joyce, Robin; Pohlman, Brad; Bartlett, Nancy L.; Wiseman, Gregory A.; Padre, Norman M.; Grillo-López, Antonio J; Multani, Pratik S.; White, Christine

doi:10.1200/jco.2002.11.076

Cited by 1,035 publications

(587 citation statements)

References 40 publications

Supporting

Mentioning

547

Contrasting

Unclassified

Order By: Relevance

“…To date, successful treatment regimens using RIT have been demonstrated, as mentioned, with FDA approved 90 Yttrium 90 Y -2B8 or Zevalin (Witzig et al, 2002), and with 131 I -B1 Tositumomab or Bexxar (Kaminski et al, 2001), both anti-CD-20 mAbs for the treatment of B-cell lymphoma. Several clinical trials are being evaluated.…”

Section: Radioisotopes Immunoconjugatesmentioning

confidence: 99%

Novel antibodies as anticancer agents

2007

View full text Add to dashboard Cite

In recent years antibodies, whether generated by traditional hybridoma technology or by recombinant DNA strategies, have evolved from Paul Ehrlich's 'magic bullets' to a modern age 'guided missile'. In the recent years of immunologic research, we are witnessing development in the fields of antigen screening and protein engineering in order to create specific anticancer remedies. The developments in the field of recombinant DNA, protein engineering and cancer biology have let us gain insight into many cancer-related mechanisms. Moreover, novel techniques have facilitated tools allowing unique distinction between malignantly transformed cells, and regular ones. This understanding has paved the way for the rational design of a new age of pharmaceuticals: monoclonal antibodies and their fragments. Antibodies can select antigens on both a specific and a high-affinity account, and further implementation of these qualities is used to target cancer cells by specifically identifying exogenous antigens of cancer cell populations. The structure of the antibody provides plasticity resonating from its functional sites. This review will screen some of the many novel antibodies and antibody-based approaches that are being currently developed for clinical applications as the new generation of anticancer agents.

show abstract

Section: Radioisotopes Immunoconjugatesmentioning

confidence: 99%

Novel antibodies as anticancer agents

2007

View full text Add to dashboard Cite

show abstract

“…Long-term follow-up of this cohort demonstrated that many of these responses were durable, indeed 24% of responders had a TTP of more than 3 years (Gordon et al, 2004). In the pivotal phase III study, 143 rituximab naive patients with relapsed or refractory disease were randomized to receive either Y 90 ibritumomab tiuxetan or rituximab administered according to the standard schedule (Witzig et al, 2002b). The majority of patients enrolled had FL, with 17 non-follicular low-grade lymphomas and 13 patients with disease transformation.…”

Section: Tositumomabmentioning

confidence: 99%

Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab

Davies

2007

Oncogene

View full text Add to dashboard Cite

Radioimmunotherapy, targeting the CD20 antigen, in B-cell lymphoma has clearly demonstrated efficacy and tolerability over the preceding 15 years. As a result, two products are available with Food and Drug Administration approval for marketing -Y 90 ibritumomab tiuxetan and I 131 tositumomab, given as the Zevalin and Bexxar therapeutic regimens, respectively. Both demonstrate high-response rates and durability of remission in the relapsed/refractory disease setting. Data are emerging regarding their utility as initial therapy, and furthermore, they are been investigated for use sequentially with chemotherapy, and in the myeloablative setting. As yet however, how to best use these agents in the clinical disease course remains uncertain.

show abstract

“…For this population of patients who had essentially exhausted other available treatment options, Zevalin was shown to be highly effective. The second pivotal study, a phase III randomized, controlled trial, was conducted among 143 patients with relapsed or refractory low-grade follicular or transformed B-cell NHL [26]. Of them, 73 patients who received the Zevalin therapeutic regimen (which includes Rituxan) showed an 80% ORR, compared to 56% ORR in the remaining 70 patients who received Rituxan alone.…”

Section: Y-ibritumomab (Zevalin ® )mentioning

confidence: 99%

Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy

et al. 2007

View full text Add to dashboard Cite

Antibodies as therapeutic agents are mostly used in oncology, as illustrated by their applications in lymphoma, breast cancer or colorectal cancer. This review provides a brief historical sketch of the development of monoclonal antibodies for cancer treatment and summarizes the most significant clinical data for the best-established reagents to date. It also discusses strategies to improve the anti-tumor efficacy of antibody therapy, including antibody gene therapy and exploitation of bone marrow derived primary mesenchymal stem cells as the antibody gene transporter.

show abstract

Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

Abstract: Radioimmunotherapy with (90)Y ibritumomab tiuxetan is well tolerated and produces statistically and clinically significant higher ORR and CR compared with rituximab alone.

Cited by 1,035 publications

References 40 publications

Novel antibodies as anticancer agents

Novel antibodies as anticancer agents

Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab

Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy

Contact Info

Product

Resources

About